ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq:

By: financialpost.com

Apr 01 2024
60
8509 Views

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 Read More

PACS Group to Announce First Quarter 2024 Financial Results

The FAA investigates after Boeing says workers in South Carolina falsified 787 inspection records

Canoe EIT Income Fund Announces May 2024 Monthly Distribution and Quarterly Distribution on Preferred Units

Hamilton Thorne to Announce Q1 2024 Financial Results and Hold Conference Call on May 14, 2024

Timbercreek Financial Announces 2024 First Quarter Results

Google sues CRTC to have YouTube ad revenue exempted from regulatory fees

A US company is fined $650,000 for illegally hiring children to clean meat processing plants

Ascot Announces Update to Its Board of Directors

Lumenix announces new partnership to address future pandemic threats in Canada and around the world

Nonprofit Chicago production house Invisible Institute wins 2 Pulitzer Prizes

Bombardier Announces Participation in Upcoming Investor Conferences

Conifex Announces First Quarter 2024 Results Conference Call

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Related